Innovation Pharmaceuticals Inc (IPIX)

[oddone33320]

Based on the Primary Outcome Defined in the Trial, it would seem that continuing to require supplemental oxygen would count against us? Presumably that would include a ventilator.

I'm wondering if the trial design for the Primary Outcome could have been made better to highlight the positive actions of Brilacidin more on the anti-viral and anti-inflammatory end of things rather than just a Primary measure for "the patient is all better now or isn't".
I may be mistaken, but even if the patient recovers from just the COVID virus itself very successfully with substantially less inflammation, any damage to the body that the virus has done prior to treatment remains and Brilacidin was never designed or intended as a regenerative medicine to restore function to damaged lungs (or other organs) - it was only designed to be an antiviral and antibacterial and anti-inflammatory. Again, unless I am mistaken, which I hope to be, it seems we might be evaluated unfairly in that regard but I hope they are able to elucidate this in the results and clearly show benefit where you would expect it based on what the drug is designed to do.